logo-loader
viewMaxCyte Inc

MaxCyte - delivering growth, highlighting value

MaxCyte (LON:MXCT) delivered a consensus-beating 30% step up in 2019 (FY19) revenues, driven by sales of licences for its proprietary cell engineering platform and early clinical milestones from some of its eight clinical/commercial licences, reaching a five-year revenue compound annualised growth rate (CAGR) of 25%. With more than US$650mln in potential pre-commercial milestones payable from its eight clinical/commercial licences with cell therapy partners, recent advances in its partners’ development programmes are set to translate into further upside to core revenues from FY20. With its novel cell therapy platform CARMA now separated into a wholly-owned subsidiary, targeting self-sufficiency by 2021, and key data due from its lead asset mid-2020, there is increasing visibility on the value and prospects of both its technology and therapeutic divisions.

 

Quick facts: MaxCyte Inc

Price: 159.9 GBX

AIM:MXCT
Market: AIM
Market Cap: £91.76 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

MaxCyte in 'exceptional position to benefit from explosive growth in gene...

Proactive Research analyst Emma Ulker gives her take on the recent trading update from MaxCyte (LON:MXCT). The firm signed five of eight clinical/commercial deals for its proprietary cell engineering Flow Electroporation technology in FY19. Ulker says the increasing momentum in deal flow...

3 weeks ago

3 min read